Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Pharmacol Biochem Behav. 2011 Sep 25;100(3):607–615. doi: 10.1016/j.pbb.2011.09.009

Fig. 5.

Fig. 5

ALO AIMs in L-DOPA-primed DA- (n = 5) and DA + NE- (n = 6) lesioned rats pretreated with 0, 2.5 and 10 mg/kg Idazoxan (IDZ) prior to 4 and 12 mg/kg L-DOPA. Nonparametric Friedman ANOVA was used to analyze treatment differences in ALO AIMs at each time point (10–180 min). A dose-dependent reduction in ALO AIMs was observed 30, 50, 80, 100, 110 and 140 min following 12 mg/kg L-DOPA in DA-lesioned rats (A). After 4 mg/kg L-DOPA, the DA lesion group showed an early IDZ-10-induced reduction in ALO AIM from 50 to 100 min followed by an increase in AIMs that was observed from 140 180 min. In addition IDZ-2.5 pretreatment worsened late AIMs at 130 and 160 min time points (B). In DA + NE lesioned rats, the high dose of IDZ dose-dependently reduced ALO AIMs at 40, 80 and 110 min following 12 mg/kg L-DOPA (C). No IDZ-induced treatment changes in ALO AIMs were observed following 4 mg/kg L-DOPA (D). *P<0.05 for Vehicle vs. PRO-5, +P<0.05 for Vehicle vs. PRO-20 and #P<0.05 for PRO-5 vs. PRO-20. All significant differences were between groups at the same time point (line graphs) or total time (insets). Data presented as median ALO AIMs ± M.A.D.